Maillard reaction and immunogenicity of protein therapeutics

doi:10.5411/wji.v6.i1.19

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 1

This Article

(497)

(397)

(0)

(15382)

(7)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Immunology

ISSN

2219-2824

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Immunol. Mar 27, 2016; 6(1): 19-38
Published online Mar 27, 2016. doi: 10.5411/wji.v6.i1.19

Full Size Figure Download Figure

Figure 9 Proposed immune responses against advanced glycation end products modified IFNβ (IFNβ-advanced glycation endproducts). AGEs: Advanced glycation endproducts.

Citation: Tsekovska R, Sredovska-Bozhinov A, Niwa T, Ivanov I, Mironova R. Maillard reaction and immunogenicity of protein therapeutics. World J Immunol 2016; 6(1): 19-38
URL: https://www.wjgnet.com/2219-2824/full/v6/i1/19.htm
DOI: https://dx.doi.org/10.5411/wji.v6.i1.19

Tsekovska R, Sredovska-Bozhinov A, Niwa T, Ivanov I, Mironova R. Maillard reaction and immunogenicity of protein therapeutics. World J Immunol 2016; 6(1): 19-38 [DOI: 10.5411/wji.v6.i1.19]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.